Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
2.480
-0.080 (-3.13%)
At close: Oct 12, 2026, 4:00 PM EDT
2.505
+0.025 (1.01%)
After-hours: Oct 12, 2026, 4:53 PM EDT
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 202 employees as of December 31, 2025. The number of employees decreased by 97 or -32.44% compared to the previous year. That makes Rocket Pharmaceuticals the 26,682nd largest employer in the world and 3,382nd in the United States.
Employees
202
Change (1Y)
-97
Growth (1Y)
-32.44%
Revenue / Employee
n/a
Profits / Employee
-$85,396
Market Cap
272.24M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 202 | -97 | -32.44% |
| Dec 31, 2024 | 299 | 31 | 11.57% |
| Dec 31, 2023 | 268 | 28 | 11.67% |
| Dec 31, 2022 | 240 | 89 | 58.94% |
| Dec 31, 2021 | 151 | 60 | 65.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Bicycle Therapeutics | 288 |
| Abeona Therapeutics | 226 |
| EyePoint | 214 |
| Nautilus Biotechnology | 127 |
| SAB Biotherapeutics | 86 |
| Larimar Therapeutics | 71 |
| X4 Pharmaceuticals | 45 |
RCKT News
- 4 days ago - Rocket Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs - TheFly
- 5 days ago - Rocket Pharmaceuticals highlights FDA-aligned Phase 2 trial of RP-A501 - TheFly
- 5 days ago - Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar - Business Wire
- 6 days ago - Rocket Pharmaceuticals Transcript: Status update - Transcripts
- 6 days ago - Rocket Pharmaceuticals Slides: Status update - Filings
- 6 days ago - Rocket Pharmaceuticals secures $150M credit facility from Hercules Capital - TheFly
- 6 days ago - Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital - Business Wire
- 26 days ago - Needham upgrades Rocket Pharmaceuticals after FDA reaffirms Danon study design - TheFly